Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer

BACKGROUND: Peritoneal carcinomatosis (PC) represents an unfavourable prognostic factor for patients with gastric cancer (GC). Intraperitoneal treatment with the bispecific and trifunctional antibody catumaxomab (EpCAM, CD3), in addition to systemic chemotherapy, could improve elimination of PC. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Knödler, Maren, Körfer, Justus, Kunzmann, Volker, Trojan, Jörg, Daum, Severin, Schenk, Michael, Kullmann, Frank, Schroll, Sebastian, Behringer, Dirk, Stahl, Michael, Al-Batran, Salah-Eddin, Hacker, Ulrich, Ibach, Stefan, Lindhofer, Horst, Lordick, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070920/
https://www.ncbi.nlm.nih.gov/pubmed/29988111
http://dx.doi.org/10.1038/s41416-018-0150-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070920/
https://www.ncbi.nlm.nih.gov/pubmed/29988111
http://dx.doi.org/10.1038/s41416-018-0150-6

Ejemplares similares